DK3256466T3 - 1-heterocyclyl-isochromanylforbindelser og analoger til behandling af cns-forstyrrelser - Google Patents
1-heterocyclyl-isochromanylforbindelser og analoger til behandling af cns-forstyrrelser Download PDFInfo
- Publication number
- DK3256466T3 DK3256466T3 DK16708262.7T DK16708262T DK3256466T3 DK 3256466 T3 DK3256466 T3 DK 3256466T3 DK 16708262 T DK16708262 T DK 16708262T DK 3256466 T3 DK3256466 T3 DK 3256466T3
- Authority
- DK
- Denmark
- Prior art keywords
- isochromanyl
- heterocyclyl
- analogs
- compounds
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562115064P | 2015-02-11 | 2015-02-11 | |
| PCT/US2016/017539 WO2016130796A1 (en) | 2015-02-11 | 2016-02-11 | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3256466T3 true DK3256466T3 (da) | 2022-05-02 |
Family
ID=55456908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16708262.7T DK3256466T3 (da) | 2015-02-11 | 2016-02-11 | 1-heterocyclyl-isochromanylforbindelser og analoger til behandling af cns-forstyrrelser |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9856238B2 (OSRAM) |
| EP (2) | EP3256466B9 (OSRAM) |
| JP (3) | JP6657241B2 (OSRAM) |
| KR (1) | KR102601972B1 (OSRAM) |
| CN (2) | CN111925360B (OSRAM) |
| AU (1) | AU2016219253C1 (OSRAM) |
| CA (1) | CA2976095C (OSRAM) |
| CY (1) | CY1125198T1 (OSRAM) |
| DK (1) | DK3256466T3 (OSRAM) |
| EA (1) | EA201791804A1 (OSRAM) |
| ES (2) | ES2967643T3 (OSRAM) |
| HU (1) | HUE058698T2 (OSRAM) |
| IL (1) | IL253914B (OSRAM) |
| MX (2) | MX392664B (OSRAM) |
| MY (1) | MY188160A (OSRAM) |
| NZ (1) | NZ735011A (OSRAM) |
| PH (1) | PH12017501422A1 (OSRAM) |
| PL (1) | PL3256466T3 (OSRAM) |
| PT (1) | PT3256466T (OSRAM) |
| SG (2) | SG11201706515QA (OSRAM) |
| UA (1) | UA122222C2 (OSRAM) |
| WO (1) | WO2016130796A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3256476T3 (pl) * | 2015-02-11 | 2019-05-31 | Pgi Drug Discovery Llc | Związki i analogi fuzyjnego dihydro-4h-pirazolo[5,1-c][1,4]oksazynylu w leczeniu zaburzeń oun |
| DK3256466T3 (da) * | 2015-02-11 | 2022-05-02 | Sunovion Pharmaceuticals Inc | 1-heterocyclyl-isochromanylforbindelser og analoger til behandling af cns-forstyrrelser |
| CN110087687A (zh) | 2016-07-29 | 2019-08-02 | 赛诺维信制药公司 | 化合物、组合物及其用途 |
| CA3032302A1 (en) | 2016-07-29 | 2018-02-01 | Taleen G. Hanania | Compounds and compositions and uses thereof |
| EP3645120B1 (en) | 2017-06-30 | 2024-12-11 | Chase Therapeutics Corporation | Nk-1 antagonist compositions and methods for use in treating depression |
| CN111183138A (zh) | 2017-08-02 | 2020-05-19 | 赛诺维信制药公司 | 异色满化合物以及用途 |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| MX2021010880A (es) | 2019-03-14 | 2022-01-18 | Sunovion Pharmaceuticals Inc | Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas. |
| US12077546B2 (en) | 2021-04-10 | 2024-09-03 | Sumitomo Pharma Co., Ltd. | Bicyclic pyridine derivative |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3438995A (en) | 1968-01-08 | 1969-04-15 | Melville Sahyun | Diazaheterocyclic substituted benz-oxaheterocyclic compounds |
| US4963568A (en) | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| US5621133A (en) | 1989-05-31 | 1997-04-15 | Deninno; Michael P. | Dopamine agonists |
| IE73232B1 (en) * | 1990-05-25 | 1997-05-21 | Akzo Nv | Isochromane derivatives |
| US5238939A (en) * | 1990-05-25 | 1993-08-24 | Akzo N.V. | Isochromane derivatives |
| WO2000000487A1 (en) | 1998-06-30 | 2000-01-06 | Eli Lilly And Company | 5-ht1f agonists |
| SE9902267D0 (sv) * | 1999-06-16 | 1999-06-16 | Astra Ab | New compounds |
| MXPA04004368A (es) * | 2001-11-08 | 2004-08-11 | Sepracor Inc | Metodos para tratar depresion y otros transtornos del sistema nervioso central utilizando desmetil-y didesmetil-metabolitos del citalopram enantiomericamente enriquecidos. |
| EP1831203A1 (en) * | 2004-12-21 | 2007-09-12 | F. Hoffmann-Roche AG | Chroman derivatives and uses thereof in the treatment of cns disorders |
| RU2007139541A (ru) | 2005-04-22 | 2009-05-27 | Вайет (Us) | Производные хромана и хромена и их применение |
| KR20080090545A (ko) * | 2006-01-27 | 2008-10-08 | 에프. 호프만-라 로슈 아게 | Ｃｎｓ 장애 치료용 2-이미다졸의 용도 |
| KR101103118B1 (ko) | 2007-11-02 | 2012-01-04 | 동아제약주식회사 | 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물 |
| SG10201401661RA (en) * | 2009-12-04 | 2014-07-30 | Sunovion Pharmaceuticals Inc | Multicycle compounds and pharmaceutical compositions useful for the treatment of neurological disorders |
| WO2012122340A1 (en) | 2011-03-10 | 2012-09-13 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
| AR090557A1 (es) * | 2012-04-02 | 2014-11-19 | Orion Corp | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 |
| JP6359560B2 (ja) * | 2012-12-31 | 2018-07-18 | サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | 複素環式化合物及びその使用方法 |
| DK3256466T3 (da) * | 2015-02-11 | 2022-05-02 | Sunovion Pharmaceuticals Inc | 1-heterocyclyl-isochromanylforbindelser og analoger til behandling af cns-forstyrrelser |
-
2016
- 2016-02-11 DK DK16708262.7T patent/DK3256466T3/da active
- 2016-02-11 SG SG11201706515QA patent/SG11201706515QA/en unknown
- 2016-02-11 MX MX2020001157A patent/MX392664B/es unknown
- 2016-02-11 JP JP2017542401A patent/JP6657241B2/ja not_active Expired - Fee Related
- 2016-02-11 EP EP16708262.7A patent/EP3256466B9/en active Active
- 2016-02-11 PL PL16708262T patent/PL3256466T3/pl unknown
- 2016-02-11 SG SG10201806809QA patent/SG10201806809QA/en unknown
- 2016-02-11 CN CN202010607608.6A patent/CN111925360B/zh active Active
- 2016-02-11 EA EA201791804A patent/EA201791804A1/ru unknown
- 2016-02-11 ES ES22166538T patent/ES2967643T3/es active Active
- 2016-02-11 EP EP22166538.3A patent/EP4046995B1/en active Active
- 2016-02-11 ES ES16708262T patent/ES2911910T3/es active Active
- 2016-02-11 HU HUE16708262A patent/HUE058698T2/hu unknown
- 2016-02-11 WO PCT/US2016/017539 patent/WO2016130796A1/en not_active Ceased
- 2016-02-11 US US15/041,852 patent/US9856238B2/en active Active
- 2016-02-11 MX MX2017010363A patent/MX371404B/es active IP Right Grant
- 2016-02-11 MY MYPI2017702923A patent/MY188160A/en unknown
- 2016-02-11 UA UAA201708945A patent/UA122222C2/uk unknown
- 2016-02-11 AU AU2016219253A patent/AU2016219253C1/en not_active Ceased
- 2016-02-11 PT PT167082627T patent/PT3256466T/pt unknown
- 2016-02-11 CA CA2976095A patent/CA2976095C/en active Active
- 2016-02-11 NZ NZ735011A patent/NZ735011A/en not_active IP Right Cessation
- 2016-02-11 CN CN201680018639.XA patent/CN107531674B/zh active Active
- 2016-02-11 KR KR1020177025290A patent/KR102601972B1/ko active Active
-
2017
- 2017-08-08 IL IL253914A patent/IL253914B/en unknown
- 2017-08-09 PH PH12017501422A patent/PH12017501422A1/en unknown
- 2017-11-21 US US15/819,372 patent/US10336732B2/en active Active
-
2019
- 2019-05-06 US US16/403,698 patent/US11192885B2/en active Active
-
2020
- 2020-02-05 JP JP2020018081A patent/JP7023994B2/ja not_active Expired - Fee Related
-
2021
- 2021-10-29 US US17/452,786 patent/US20220185799A1/en not_active Abandoned
-
2022
- 2022-02-09 JP JP2022018580A patent/JP2022065050A/ja active Pending
- 2022-05-20 CY CY20221100352T patent/CY1125198T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3224269T3 (da) | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser | |
| DK3570844T3 (da) | Azolopyrimidin til behandlingen af kræftrelaterede lidelser | |
| DK3185876T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser | |
| DK3206493T3 (da) | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser | |
| DK3250210T3 (da) | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser | |
| DK3600270T3 (da) | Forbindelser og sammensætninger til behandling af hæmatologiske lidelser | |
| IL247452A0 (en) | Compounds for treatment of complement mediated disorders | |
| DK3261640T3 (da) | 5ht-agonister til behandling af epilepsilidelser | |
| DK3277815T3 (da) | Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser | |
| DK3307262T3 (da) | Forbindelser til anvendelse ved behandling af neuromuskulære lidelser | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3119797T3 (da) | Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose | |
| DK3143025T3 (da) | Forbindelser til behandling af spinal muskelatrofi | |
| DK3325443T3 (da) | Fremgangsmåde til fremstilling af pridopidin | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3102213T3 (da) | Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser | |
| DK3433266T3 (da) | Fremgangsmåder til behandling af mitokondrieforstyrrelser | |
| DK3256466T3 (da) | 1-heterocyclyl-isochromanylforbindelser og analoger til behandling af cns-forstyrrelser | |
| DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3265087T3 (da) | Fremgangsmåde til behandling med tradipitant | |
| DK3324824T3 (da) | Fremgangsmåde til behandling af binokulare dysfunktioner | |
| DK3261661T3 (da) | Menotropin til behandling af infertilitet | |
| DK3192524T3 (da) | Hgf præparat egnet til behandling af neurologiske lidelser | |
| DK3515455T3 (da) | Forbindelser til behandling af lidelser i lipoproteinmetabolismen |